Nimotuzumab combined with gemcitabine and nab-paclitaxel as first-line therapy for advanced pancreatic cancer: a single-arm, single-center Phase II prospective study
Frontiers in Medicine · 29.05.2026 · 13
DOI: 10.3389/fmed.2026.1838482 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Frontiers in Medicine, online erschienen am 29.05.2026. Verfasst von Lin Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Shenzhen University, The Second People's Hospital of Shenzhen, Shenzhen, China. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Pancreatic cancer remains one of the most lethal malignancies, with a five-year survival rate of merely 8% for exocrine tumors, and conventional chemotherapy offering limited clinical benefit. Nab-paclitaxel plus gemcitabine (AG) is a standard first-line regimen, yet outcomes remain suboptimal. Nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody with a favorable tolerability profile, has demonstrated promising activity in combination with gemcitabine in KRAS wild-type pancreatic cancer.
Objective
This study aimed to preliminarily evaluate the efficacy and safety of nimotuzumab combined with gemcitabine and nab-paclitaxel (NTZ-AG) as first-line therapy in patients with locally advanced or metastatic pancreatic cancer.
Methods
This single-arm, single-center Phase II prospective study enrolled 16 patients (aged 18–75 years, ECOG PS 0–1) with pathologically confirmed Stage III–IV pancreatic cancer without prior systemic chemotherapy. Patients received nimotuzumab 400 mg (day 1, 3-h infusion), gemcitabine 1,000 mg/m 2 (days 1 and 8), and nab-paclitaxel 125 mg/m 2 (days 1 and 8) every 21 days for up to 6 cycles. The primary endpoint was objective response rate (ORR), assessed per RECIST v1.1; secondary endpoints included progression-free survival (PFS), overall survival (OS), clinical benefit rate (CBR), duration of response (DOR), and safety, graded per NCI-CTCAE v5.0.
Results
Among 16 evaluable patients, the ORR was 68.75% (11/16; 95% CI: 42.81–87.34%), with no complete responses and 11 partial responses. The disease control rate (DCR) was 100%. Median PFS was 6.0 months (95% CI: 4.06–7.95) and median OS was 12.0 months (95% CI: 8.35–15.66), with one patient achieving an OS of 49 months. Adverse events were predominantly Grade 1–2; no Grade 4 or higher toxicities were observed. Grade 3 events included alopecia (81.2%), nausea (12.5%), and myelosuppression.
Conclusion
The NTZ-AG regimen demonstrated meaningful anti-tumor activity and an acceptable safety profile as first-line therapy for unselected advanced pancreatic cancer patients, providing a rational basis for larger randomized controlled trials. Clinical trial registration This trial was registered at the Chinese Clinical Trial Register (ChiCTR) under the registration number ChiCTR2300072843 having URL https://www.chictr.org.cn/showprojEN.html?proj=198791 .
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, The First Affiliated Hospital of Shenzhen University, The Second People's Hospital of Shenzhen, Shenzhen, China.
- Shenzhen University, Shenzhen, China.
- School of Public Health, Southern Medical University, Guangzhou, China.
- Department of Oncology, Sanya Central Hospital (Hainan Third People's Hospital), Sanya, China.
Zitieren
APA
Lin, L., Zhao, X., Luo, Y., Cai, J. H., Lin, Z., Xiao, L., Tian, G., & He, S. (2026). Nimotuzumab combined with gemcitabine and nab-paclitaxel as first-line therapy for advanced pancreatic cancer: a single-arm, single-center Phase II prospective study. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1838482
Vancouver
Lin L, Zhao X, Luo Y, Cai JH, Lin Z, Xiao L, et al. Nimotuzumab combined with gemcitabine and nab-paclitaxel as first-line therapy for advanced pancreatic cancer: a single-arm, single-center Phase II prospective study. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1838482
BibTeX
@article{Lin2026,
author = {Lin, Lin and Zhao, Xinyi and Luo, Yawen and Cai, Jia-Hua and Lin, Zhihuan and Xiao, Liang and Tian, Geng and He, Shaozhong},
title = {Nimotuzumab combined with gemcitabine and nab-paclitaxel as first-line therapy for advanced pancreatic cancer: a single-arm, single-center Phase II prospective study},
journal = {Frontiers in Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fmed.2026.1838482}
}
EUVIMED